Introduction
============

Organizing pneumonia (OP), which was previously called bronchiolitis obliterans organising pneumonia, is a well-known clinicopathological entity ([@b1-etm-0-0-5393]--[@b3-etm-0-0-5393]) that is associated with non-specific clinical manifestations. Lange initially described OP in 1901 ([@b2-etm-0-0-5393]) and Epler *et al* ([@b4-etm-0-0-5393]) published the largest case series of OP in 1985. OP is considered a rare disease with an incidence of 1.96/100,000 ([@b3-etm-0-0-5393]); however, incidence has reportedly been increasing since the 1980s ([@b2-etm-0-0-5393]).

OP may be characterized as primary or secondary OP based on etiology. Primary OP is referred to as cryptogenic organizing pneumonia (COP) ([@b1-etm-0-0-5393]), has no known cause and is classified as an idiopathic interstitial pneumonia. Secondary OP is associated with various factors, including pathological infection (especially by *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and various types of virus ([@b5-etm-0-0-5393]), connective tissue diseases, malignancies, administration of various agents, chemotherapy, radiotherapy, organ transplantation ([@b3-etm-0-0-5393]), the inhalation of harmful gases ([@b1-etm-0-0-5393],[@b2-etm-0-0-5393]) and certain occupations or environments ([@b6-etm-0-0-5393]). As OP may be idiopathic or associated with a known underlying disease, delayed diagnosis or mis diagnosis is likely to occur ([@b7-etm-0-0-5393]).

The characteristic clinical features of OP are typically non-specific and include constitutional symptoms with flu-like illness. Common clinical manifestations of OP include cough, dyspnea, fever and weight loss ([@b2-etm-0-0-5393],[@b7-etm-0-0-5393]). Hemoptysis has rarely been reported as the primary presenting symptom of OP ([@b2-etm-0-0-5393]). The present case report details a Chinese case of COP with hemoptysis as the primary and unique clinical manifestation.

A literature review was carried out and a total of 23 studies published between 1995 and 2015 were included. A total of 119 COP cases were compared and analyzed for clinical manifestations, imaging manifestations, treatment and prognosis. The results of the review indicated that diagnosis of COP with lung cancer was challenging and COP was sometimes treated excessively, for example surgery was performed when steroids would have been sufficient, however the majority of patients with COP had a relatively good prognosis.

Case report
===========

A 61-year-old Chinese male patient was presented with bloody sputum at Beijing Tiantan Hospital, Beijing, China, in August 2015. The chest X-ray revealed an abnormal shadow. The patient had no other chronic diseases such as hypertension or diabetes and no history of alcohol abuse or smoking. The results of human immunodeficiency virus and hepatitis B virus testing were negative.

Laboratory tests detected a white blood cell count of 4.92×10^9^/l (normal range, 4.0--10.0×10^9^/l), neutrophil percentage of 58.8% (normal range, 51.0--75.0%), lymphocyte percentage of 31.7% (normal range, 20--40%), monocyte percentage of 8.1% (normal range, 3.0--8.0%), eosinophil percentage of 1.0% (normal range, 0.5--5.0%), basophils percentage of 0.4% (normal range, 0--1.0%), red blood cell count of 4.88×10^12^/l (normal range, 4.0--5.5×10^12^/l), hemoglobin concentration of 145 g/l (normal range, 120--160 g/l), platelet count of 184×10^9^/l (normal range, 100--300) ×10^9^/l) and C-reactive protein level of 0.04 mg/dl (normal range, 0.0--0.6 mg/dl). Hepatic and renal functions and glucose and lipid levels in blood circulation were within normal ranges. Carbohydrate antigen 125, cytokeratin-19 fragment, neuron-specific enolase, squamous cell carcinoma associated antigen, carcino embryonic antigen and pro-gastrin-releasing peptide levels were within normal ranges.

Chest enhanced computed tomography scanning revealed a 3.0×1.1×2.0 cm irregular mass with rough edges and inhomogenous density in the apical region of the right upper lobe ([Fig. 1](#f1-etm-0-0-5393){ref-type="fig"}). Pleural pull signs were visible around the mass. The lung demonstrated limitations of pulmonary emphysema. No marked swelling was observed in the lymph nodes in the mediastinal area and bilateral hilum of the lung. There was no effusion in the bilateral thorax and pericardium. Positron emission tomography-computed tomography scan with fluorin-18 fluorodeoxyglucose further revealed a high radioactivity uptake of this agent at the mass and a maximum standardized uptake value of 14.1 was recorded ([Fig. 1](#f1-etm-0-0-5393){ref-type="fig"}). The mass appeared lobulated with surrounding burrs, and pleural pull signs were observed in the surrounding area. Primary malignant tumor was suspected from the imaging results.

Bronchoscopy revealed a normal tracheal mucosa and lumen. Pulmonary function tests presented normal volume and ventilatory function. Electrocardiogram examination returned normal results.

A surgical procedure was performed for the diagnosis and treatment of the mass. A partial resection including the mass was performed prior to frozen section examination. The lesion tissue and surrounding normal tissue were removed and kept dry. Tissue blocks were placed on a cold stage for embedding with Richard-Allan Neg 50 frozen section embedding medium (Thermo Fisher Scientific Inc., Waltham, MA, USA). Following quick-freezing (−25-30°C) for 2 min and samples were sliced into sections 3--5 µm thick. Sections were then attached to slides and fixed with fixing fluid composed of 95 ml 95% ethanol and 5 ml glacial acetic acid (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) for 1--2 min at room temperature. Hematoxylin-eosin (Baso diagnostics Inc., Zhuhai, China) staining was then performed at room temperature for 8--12 min. Examination of frozen sections revealed infiltration by numerous inflammatory cells with fibrous tissue hyperplasia; however, no apparent malignant tumor was identified. Wedge resection of the upper lobe of the right lung was successfully implemented via thoracoscope surgery. On the day following surgery, bedside chest X-ray examination was performed, which confirmed that the mass was completely removed. Electrocardiogram monitoring and blood routine examination results were within normal ranges. Atomization inhalation treatment with ipratropium bromide solution (500 µg; Shanghai Boehringer Ingerhan Pharmaceutical Co., Ltd, Shanghai, China) was administered 3 times per day for three days following surgery, Cefminox sodium (2 g, Qilu Pharmaceutical Co., Ltd, Jinan, China) was infused intravenously twice 1 day following surgery to prevent postoperative infection and Flurbiprofen axetil (100 mg, Beijing Ted Pharmaceutical Co., Ltd, Beijing, China) was infused intravenously twice per day two days following surgery for postoperative analgesia.

Pathological examinations revealed typical characteristics of OP. The alveoli and alveolar ducts were filled with plugs of granulation tissue, which were composed of fibroblasts. Furthermore, chronic inflammatory cell infiltration and a few scattered mononuclear macrophages were detected in tissue sections ([Fig. 2](#f2-etm-0-0-5393){ref-type="fig"}).

The symptom of hemoptysis disappeared following the surgical resection and the patient recovered well. As no other lesions were detected in the lung, corticosteroid administration was not considered and follow-up observation was recommended for the patient. Informed consent was obtained from the patient prior to inclusion in the present report.

Literature review
=================

### Literature search

A search of the literature was performed using Medline (<http://medline.com>) with the keywords 'bronchiolitis obliterans organizing pneumonia OR cryptogenic organizing pneumonia AND lung cancer' and 'bronchiolitis obliterans organizing pneumonia OR cryptogenic organizing pneumonia AND case report'. Studies on secondary OP were excluded and a total of 23 studies ([@b1-etm-0-0-5393],[@b2-etm-0-0-5393],[@b5-etm-0-0-5393],[@b6-etm-0-0-5393],[@b8-etm-0-0-5393]--[@b26-etm-0-0-5393]) were retrieved by December 2015.

From these 23 studies, data was reviewed from 119 patients with COP diagnosed between 1995 and 2015 published in PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) and ELSEVIER (<https://www.elsevier.com/>). The 119 patients included 78 males and 41 females who ranged in age from 37--88 years. The characteristics of these cases are detailed in [Table I](#tI-etm-0-0-5393){ref-type="table"}. Pulmonary function tests typically revealed a mild to moderate restrictive pattern.

### Clinical manifestations

Among the 119 reviewed cases, patient clinical symptom information was obtained from 114. Of these 114 cases, 20 (17.5%) demonstrated no symptoms. Flu-like respiratory symptoms, such as cough and fever were the most common symptoms. Cases including cough accounted for 52.6% (n=60), fever accounted for 44.7% (n=51) and dyspnea accounted for 43.0% (n=49). Clinical manifestations were various and non-specific, including hemoptysis (n=15; 13.2%), malaise (n=10; 8.7%), wheezing (n=9; 7.9%), chest pain (n=4; 3.5%), weight loss (n=4; 3.5%), expectoration (n=3; 2.6%), sweats (n=2; 1.8%), fatigue (n=2; 1.8%), anorexia (n=1; 0.9%), depression (n=1; 0.9%) and generalized muscle and joint pain (n=1; 0.9%). Although cases including hemoptysis accounted for 13.2%, it rarely occurred alone and was typically accompanied by other symptoms. Joint pain and myalgia (n=1, 0.9%) were also infrequent ([@b23-etm-0-0-5393]).

### Imaging manifestations

Imaging appearances of COP cases were polymorphous and non-specific, but various presentation forms had been recently recognized as more characteristic to the diagnosis ([@b26-etm-0-0-5393]). In the 119 reviewed cases, the most common manifestations were multiple or single consolidation (n=48; 40.3%), lung nodules (n=43; 36.1%), migratory sign (n=34; 28.6%), reversed halo sign (n=33; 27.7%), multiple ground-glass opacity (n=27; 22.7%), pleural effusion (n=18; 15.1%), multiple patchy opacities (n=8; 6.7%) and air bronchogram (n=5; 4.2%).

### COP accompanied by lung cancer

Among these cases, 3 male patients were reported to have exhibited COP accompanied by lung cancer: A 73-year-old patient exhibited COP and adenocarcinoma ([@b18-etm-0-0-5393]), a 65-year-old patient exhibited COP and endobronchial squamous cell carcinoma ([@b5-etm-0-0-5393]), and a 60-year-old patient exhibited COP and bronchogenic carcinoma ([@b13-etm-0-0-5393]). These cases exhibited predominant clinical and radiological signs of COP ([@b5-etm-0-0-5393],[@b13-etm-0-0-5393],[@b18-etm-0-0-5393]). Frequently, small foci of OP accompanied lung cancer infiltrations. OP was sometimes observed as a reaction to radiotherapy or chemotherapy, but it was rarely a predominant lesion in the course of lung cancer ([@b5-etm-0-0-5393]).

Due to the presentation of the two diseases being very similar, occasional misdiagnosis or missed diagnosis is inevitable. Morichika ([@b27-etm-0-0-5393]) *et al* reported a case of a 68-year-old man diagnosed with invasive mucinous adenocarcinoma of the lung. Computed tomography demonstrated subpleural ground-glass opacity and small nodules with cavitation. Repeated bronchoscopy revealed no atypical cells, but the surgical biopsy specimen was diagnostic for adenocarcinoma. Lung cancer should be excluded in the differential diagnosis of patients with clinical features of OP.

### Diagnosis and treatment

Glucocorticoids were confirmed to be administered in 41/119 (34.5%) cases, and the majority of these cases exhibited a good clinical response, whereas only 2/41 (4.9%) did not respond. Invasive surgeries were implemented in the majority of cases (n=117; 98.3%) to make a definite diagnosis or for further treatment while information was not available on one of the remaining cases and the other was successfully treated using drugs alone. The number of patients diagnosed by cytology or pathology were as follows: Transbronchial lung biopsy, 4 (3.4%); percutaneous lung biopsy, 2 (1.7%); thoracoscopy, 4 (3.4%); open lung biopsy, 6 (5.0%); bronchoscopy and thoracotomy, 2 (1.7.%); partial resection using an endoscopic linear cutter, 1 (0.9%); percutaneous lung biopsy and open-chest partial excision, 1 (0.9%); traditional surgical methods, including wedge resection and lobectomy, 23 (19.3%); the full details of 3 (2.52%) cases were not described; 1 case (0.9%) was cured with drugs without biopsy; and 72 (60.5%) cases in reference 20 were not clearly described. Considering the benign nature of OP and the efficacy of steroids, major pulmonary resections should be avoided ([@b6-etm-0-0-5393]).

Among the 119 cases, 2 patients succumbed (1.7%), the prognosis of 2 cases was not available (1.7%), local recurrence occurred in 2 cases (1.7%), marginal recurrence occurred in 1 case (0.9%), 72 cases (60.5%) in reference 20 were not clearly described, but the majority of them recovered or were relieved. The remaining cases were recovered or relieved. Overall, the prognosis of COP was relatively good.

Discussion
==========

COP is a rare disease that occurs in both men and women with reports increasing in frequency ([@b26-etm-0-0-5393]). The illness is not known to be associated with smoking ([@b2-etm-0-0-5393]). The diagnosis of OP requires a multidisciplinary approach combining clinical and radiological expertise, with histopathological evidence when a lung biopsy has been performed ([@b26-etm-0-0-5393]). Sometimes, OP may simulate lung cancer ([@b18-etm-0-0-5393]) or coexist with lung cancer ([@b26-etm-0-0-5393]). As such, it may be difficult but necessary to make differential diagnosis between OP and lung carcinoma.

OP and lung cancer typically exhibit similar clinical manifestations. Clinical manifestations of OP are non-specific. The typical presentation is of a subacute or chronic clinical course with fever, cough, weight loss and dyspnea, and less commonly with chest pain and hemoptysis ([@b2-etm-0-0-5393]), whereas lung cancer is typically characterized by chest pain and hemoptysis. For central-type lung cancer, clinical manifestations typically include irritating cough, dyspnoea, asthma, recurrent pneumonia, hemoptysis, and nerve compression symptoms ([@b28-etm-0-0-5393]). For peripheral lung cancer, chest pain, dyspnoea and pleural effusion are common clinical symptoms ([@b28-etm-0-0-5393]).

It is difficult to distinguish lung cancer and OP from imaging, as they are diseases characterized by abnormal pulmonary shadows ([@b5-etm-0-0-5393],[@b6-etm-0-0-5393]). Lung cancer typically shows irregular nodules or masses with an obscure boundary ([@b3-etm-0-0-5393]). Lobulation, spiculation, pleural invasion and lymph node metastases are also common clinical manifestations ([@b28-etm-0-0-5393]). OP may also present in the form of solid, mixed density, or, more rarely, ground-glass nodules. Typical radiological evidence of OP includes the presence of opacity, or consolidations with ground-glass appearance and lesions may migrate, with bilateral and peripheral distribution ([@b29-etm-0-0-5393]). Ground-glass opacity surrounding the OP lesion is a common sign, which typically indicates interstitial fibrosis and chronic inflammatory cell infiltration with a patchy area of polypoid granulation tissue ([@b3-etm-0-0-5393]). The most specific indicators of OP were peri lobular abnormalities, reverse halo sign, radial bands of consolidation containing an air bronchogram, and evolution and migration of the lesions over time ([@b5-etm-0-0-5393],[@b26-etm-0-0-5393]), whereas tumor lesions are stationary. Furthermore, lymph node enlargement and pleural fluid are rarely observed in OP, but are often reported in lung carcinoma.

The pathologic OP pattern typically occurs in patients with lung cancer ([@b18-etm-0-0-5393]). OP is characterized by granulation tissue plugs within the lumens of small airways extending into the alveolar ducts and airways ([@b2-etm-0-0-5393],[@b3-etm-0-0-5393],[@b7-etm-0-0-5393]). Inflammatory debris fill the alveoli and spread to the alveolar ducts and terminal bronchioles, with characteristic endoluminal buds of granulation tissue known as Masson bodies ([@b26-etm-0-0-5393]). The clusters of granulation tissue, which are composed of fibroblasts and myofibroblasts, form as a result of non-specific tissue repair ([@b23-etm-0-0-5393]).

OP may accompany lung cancer as a result of the direct influence of a tumor on the surrounding lung parenchyma, or as a consequence of bronchial obstruction ([@b5-etm-0-0-5393]). Furthermore, anticancer treatment, including chemotherapy and radiotherapy, has been demonstrated to induce OP ([@b5-etm-0-0-5393]).

At present, the more common treatment methods are systemic corticosteroids therapy and surgical therapy. In 2013, an official statement from the American Thoracic Society/European Respiratory Society ([@b30-etm-0-0-5393]) recommended the following monitoring strategy of COP: Short-term observation to confirm treatment response and long-term observation to ensure that the response is preserved. Therefore, long-term follow-up observation is often necessary.

COP is not responsive to antibiotic therapy ([@b7-etm-0-0-5393]). Treatment with systemic corticosteroids typically achieves rapid improvement in symptoms and has a \>65% cure rate, without significant sequelae ([@b2-etm-0-0-5393],[@b23-etm-0-0-5393]). The most effective therapy is long-term administration of corticosteroids at high doses that are gradually increased during a treatment period of 6--12 months ([@b29-etm-0-0-5393]). However, when the corticosteroids are withdrawn or the dosage is decreased, COP may reoccur ([@b7-etm-0-0-5393]). In addition, prolonged treatment with corticosteroids is often associated with complications, including osteoporosis and trigger infection in diverse organs and systems, for example inhaling glucocorticoids may cause oral candidiasis infection, so patients are advised to use mouthwash after using inhaled glucocorticoids in order to avoid the occurrence of adverse reactions ([@b7-etm-0-0-5393]). Conversely, some patients may improve without treatment and spontaneous regressions have been observed ([@b3-etm-0-0-5393],[@b5-etm-0-0-5393]). Treatment regimens with corticosteroids are not completely defined at present ([@b23-etm-0-0-5393]).

Lung biopsy or a pulmonary resection is often required to enable a definitive diagnosis ([@b26-etm-0-0-5393]). Transbronchial lung biopsy and percutaneous lung biopsy are frequently used techniques, but sampling limitation from the two techniques may lead to misdiagnosis as small biopsy tissues may not represent the intrinsic lesion ([@b25-etm-0-0-5393]). A full resection of the lesions and histopathological examination of the larger organization are typically necessary ([@b31-etm-0-0-5393]). Furthermore, thoracoscopy has become a common surgical method ([@b32-etm-0-0-5393]). In view of OP\'s benign nature and the efficacy of steroid therapy, unnecessary pulmonary resection should be avoided ([@b3-etm-0-0-5393]).

In conclusion, the present report detailed a case of COP with hemoptysis as the primary clinical manifestation, which resembled and was mistaken for lung cancer. The patient recovered well following wedge resection of the upper lobe of the right lung via thoracoscope. The present case demonstrated that it is difficult to make differential diagnosis between OP and pulmonary carcinoma, and pulmonary carcinoma should be excluded prior to the diagnosis of OP.

OP is a non-specific inflammatory process caused by various injuries of either definite or idiopathic etiology. Its clinical symptoms and imaging manifestations were varied without specific characteristics, and it may be confused with other lung diseases, especially pulmonary tumor. Occupying lesions and other types of lesions should be excluded prior to the diagnosis of OP. It is difficult to distinguish OP and lung cancer from clinical symptoms and imaging findings alone, and definite diagnosis typically requires pathological examination results.

Treatment with systemic corticosteroids is often effective; however, it typically requires a lengthy treatment period and is accompanied by adverse side effects. Available treatments at present have yet to achieve desirable therapeutic efficacy.

Considering the possibility that OP may coexist with lung carcinoma, small sample biopsy may not necessarily distinguish between the diseases, and large sample pathological examination may be required. Surgery is an adequate treatment, but may be excessive. At present, the thoracoscope is the most commonly used method.

Improvement of diagnostic techniques is required, and further research should be conducted to identify more effective therapeutic methods, in order to reduce or avoid trauma to patients from unnecessary surgeries.

![Radiological presentation. (A) Chest computed tomography viewed on the lung window (axial and coronal) indicated a 3.0×1.1×2.0 cm irregular mass (arrow) with rough edges, which is called 'spiculation sign' in the upper lobe of the right lung. Pleural pull signs were visible around the mass. (B) Mediastinal window of chest enhanced computed tomography scan indicated the inhomogenous density of the mass (arrow). (C) Positron emission tomography-computer tomography scanning of the chest indicated a strong accumulation of fluorin-18 fluorodeoxyglucose (arrow) in the upper lobe of the right lung and the maximum standardized uptake value (SUV) was 14.1.](etm-15-01-0039-g00){#f1-etm-0-0-5393}

![Pathological presentation presented using Hematoxylin and eosin staining. (A) Alveoli and alveolar ducts were filled with granulation tissue (arrow). Magnification, ×40. (B) Alveolar spaces were occupied by fibrous tissue cells and multinuclear giant cells (arrow). Magnification, ×100.](etm-15-01-0039-g01){#f2-etm-0-0-5393}

###### 

Literature review of reported cases of cryptogenic organizing pneumonia (1995--2015).

  Author (year)                        Mean age, years (n, gender)   Associated conditions                                                             Clinical symptoms                                                                     Imaging manifestations                                                                                                                               Therapeutic method                                                Type of biopsy           Outcome                                                (Refs.)
  ------------------------------------ ----------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------ ------------------------------------------------------ ------------------------
  Sanito NJ *et al* (1995)             47 (1, M)                     HIV, PCP                                                                          C, F, S, W, WL                                                                        Consolidation, mass lesions                                                                                                                          Corticosteroid, TS                                                TS                       Relieved                                                 ([@b8-etm-0-0-5393])
  Haro M *et al* (1995)                58 (1, FM)                    NA                                                                                F, Ws, C                                                                              Multiple cavitary nodules                                                                                                                            Corticosteroid                                                    OLB                      Recover                                                  ([@b9-etm-0-0-5393])
  Pérez de Llano LA *et al* (1998)     66 (1, FM)                    NA                                                                                F, D, C                                                                               Bilateral patchy opacification                                                                                                                       Corticosteroid                                                    OLB                      Chronic                                                ([@b10-etm-0-0-5393])
  Stey C *et al* (1999)                80 (1, M)                     PMR                                                                               BASSP, C, D, Ma, Fa, De, WL                                                           Alveolar consolidation                                                                                                                               Corticosteroid                                                    TBLB                     Relieved                                               ([@b11-etm-0-0-5393])
  Alcolea S *et al* (2004)             37 (1, FM)                    NA                                                                                C, PE, F, WL                                                                          Consolidation, infracarinal nodes, air bronchogram                                                                                                   Corticosteroid                                                    TBLB                     Recover                                                ([@b12-etm-0-0-5393])
  Arrabal Sánchez R (2004)             60 (1, M)                     HP, T2DM, NSCLC                                                                   Cf, F                                                                                 Nodule, Air bronchogram                                                                                                                              Corticosteroid                                                    TS                       Recover                                                ([@b13-etm-0-0-5393])
  Husain SJ *et al* (2004)             76 (1, FM)                    NA                                                                                D, C, F, CP                                                                           Bilateral patchy alveolar opacities                                                                                                                  Corticosteroid                                                    OLB                      Relieved                                               ([@b14-etm-0-0-5393])
  Hooi LN (2005)                       43 (1, FM)                    Thyroid operation                                                                 C, F, MSOB                                                                            Patchy alveolar opacities                                                                                                                            Corticosteroid                                                    TS                       Relieved                                               ([@b15-etm-0-0-5393])
                                       67 (1, M)                     Cholelithiasis, Thyroid nodule, Adrenal nodule                                    C, BL, H, DM                                                                          A lesion with irregular spiculated margins                                                                                                           Corticosteroid                                                    CT-PTLB                  Relieved                                               
  Melloni G *et al* (2007)             63 (M, 15; FM, 6)             COPD (n=14), WG (n=1), Neoplastic disease (n=2), recurrent lung infections(n=8)   8 patients (38%) were symptomatic: C(n=5), F(n=1), CP(n=1), H(n=1)                    Nodules (n=12), masses(n=5), bilateral lesions (n=4), nodules and masses with an irregular margin (80%)                                              WR (n=16), LE (n=5), Corticosteroid (n=21)                        WR (n=16), LE (n=5)      Curative (n=15), local relapse (n=2), relieved (n=4)     ([@b6-etm-0-0-5393])
  Radzikowska E *et al* (2007)         65 (1, M)                     HP, SCC                                                                           F, C, D, CP                                                                           Consolidation, irregular peripheral area, air bronchogram                                                                                            TC                                                                BS                       Recover                                                  ([@b5-etm-0-0-5393])
  Burke L (2010)                       40 (1, FM)                    IHD, MI, hypothyroidism, fibromyalgia, migraines                                  SB, C, F, CP, S                                                                       Consolidation, reverse-halo sign                                                                                                                     Antibiotics, diuretic, corticosteroid                             OLB                      Relieved                                               ([@b16-etm-0-0-5393])
  Maimon N (2010)                      47 (1, FM)                    Kidneys stones with laparotomy, uterine embolisation                              C, F, D, Fa                                                                           Diffuse bilateral ground-glass, Pulmonary opacities, reverse-halo sign                                                                               Corticosteroid                                                    OLB                      Recover                                                ([@b17-etm-0-0-5393])
  Eguchi T *et al* (2011)              73 (1, M)                     Adenocarcinoma                                                                    NA                                                                                    Shadow                                                                                                                                               LE                                                                PR-ELC                   Marginal recurrence                                    ([@b18-etm-0-0-5393])
  Narasimhaiah DH *et al* (2011)       75 (1, M)                     Partial gastrectomy, Duodenectomy for duodenal ulcer                              H, T, Ho, Tc                                                                          Consolidation                                                                                                                                        Corticosteroid                                                    Postmortem               Mortality                                                ([@b2-etm-0-0-5393])
  Lee J *et al* (2011)                 38 (1, FM)                    NA                                                                                C, D                                                                                  Bilateral patchy alveolar opacities, patchy consolidation with ground glass opacities                                                                Corticosteroid, cyclosporine, macrolide                           TS                       Relieved                                               ([@b19-etm-0-0-5393])
  Pardo J *et al* (2012)               47 (M, 51; FM, 21)            NA                                                                                Incidental finding (n=7), D (n=41), C (n=38), F (n=34), H (n=11), Ma (n=9), W (n=6)   Consolidations(n=41), ground-glass (n=19), nodules (n=22), migratory sign (n=34), pleural effusion (n=17), septal (n=48), reverse-halo sign (n=31)   Corticosteroid                                                    OLB, TS, TBLB, CNB, Pe   Relieved or mortality or chronic                       ([@b20-etm-0-0-5393])
  Sheikh IA *et al* (2012)             45 (1, M)                     HIV                                                                               C, WSWOB, F, A, WL, MJP                                                               Bibasilar cystic vs. cavity lesions, ground-glass opacities                                                                                          Corticosteroid, ceftriaxone, azithromycin, VATS                   BS                       Relieved                                               ([@b21-etm-0-0-5393])
  Terada T (2013)                      73 (1, M)                     NA                                                                                Flu-like sickness, F, Cy, RL                                                          Masson\'s bodies                                                                                                                                     Corticosteroid, antibiotics                                       Autopsy                  Mortality                                              ([@b22-etm-0-0-5393])
  Utrilla Contreras C *et al* (2014)   56 (1, FM)                    NA                                                                                C, D                                                                                  Bilateral alveolar opacities, ground-glass opacities with interlobular septal thickening ('crazy-paving' pattern)                                    NA                                                                OLB                      NA                                                     ([@b23-etm-0-0-5393])
  Sugiura K *et al* (2014)             57 (1, M)                     lcSSc                                                                             NA                                                                                    Nodule with multiple cystic structures, ground-glass opacities                                                                                       Open-chest partial excision                                       PCLB, OCPE               NA                                                     ([@b24-etm-0-0-5393])
  S. Zannoni, *et al* (2015)           88 (1, FM)                    NA                                                                                F, D                                                                                  Pleural effusions                                                                                                                                    Corticosteroid                                                    NA                       Recover                                                ([@b25-etm-0-0-5393])
  Nakahara Y *et al* (2015)            69 (M, 2; FM, 3)              NTM lung disease                                                                  C (n=2), F(n=2)                                                                       Infiltrating shadows (n=2), nodules (n=4), air bronchogram (n=2), ground-glass opacities(n=1)                                                        Corticosteroid, rifamrifampicin, clarithromycin, ethambutol, LE   LE, TBLB                 Relieved                                               ([@b26-etm-0-0-5393])
  Ding QL *et al* (2015)               58 (1, FM)                    HP                                                                                C, F, Fa                                                                              Bilateral nodular, patchy alveolar opacities, thickened pleura, patchy ground-glass opacities                                                        Azithromycin, corticosteroid                                      PCLB                     Recover                                                  ([@b1-etm-0-0-5393])

M, male; HIV, human immunodeficiency virus; PCP, pneumocystis cariniipneumonia; C, cough; F, fever; S, sweats; W, wheeze; WL, weight loss; TS, thoracoscopy; FM, female; NA, not available; Ws, weakness; OLB, open lung biopsy; D, dyspnea; PMR, polymyalgia rheumatic; BASSP, bilateral aches and stiffness involving the shoulders and pelvic girdle; Ma, malaise; Fa, fatigue; De, depression; TBLB, trans-bronchial lung biopsy; PE, purulent expectoration; HP, Hypertension; T2DM, Type2 diabetes mellitus; NSCLC, non-small cell lung cancer; Cf, confusion; CP, chest pain; MSOB, mucoid sputum occasionally bloodstained; BL, breathlessness; H, hemoptysis; DM, diabetes mellitus; CT-PTLB, CT scan guided percutaneous trucut lung biopsy; COPD, chronic obstructive pulmonary disease; WG, Wegener\'s granulomatosis; WR, wedge resection; LE, lobectomy; SCC, squamous cell carcinoma; TC, thoracotomy; BS, bronchoscopy; IHD, ischaemic heart disease; MI, Myocardial infarction; SB, shortness of breath; PR-ELC, partial resection using an endoscopic linear cutter; T, tachypnoeic; Ho, hypoxic; Tc, tachycardic; CNB, core needle biopsy; Pe, pneumectomy; WSWOB, whitish sputum without blood; A, anorexia; MJP, muscle and joint pains; VATS, video assisted thoracic surgery; Cy, cyanosis; RL, rale in lung; lcSSc, limited cutaneous systemic sclerosis; PCLB, percutaneous lung biopsy; OCPE, open-chest partial excision; NTM, non-tuberculous mycobacterial.
